All News
View More
Medicaid Changes Could Burden Hospitals and Strain Community Health Plans
Healthcare Reform: Employers and Narrow Networks Could Drive Cost-Effective Patient Outcomes

Employers and Medicare trustees could come together and change the healthcare industry, leading to healthcare reform, according to Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company.

FDA Approves Amvuttra for ATTR-CM in Extended Label

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.

Email Remains a Leading Security Risk in Healthcare

It was found that Microsoft 365 was the most frequently compromised platform, responsible for 43.3% of breaches.

Should MAHA Tackle the Chronic Disease Epidemic with Preventative Care?

Luke Hansen, M.D., M.H.S., chief medical officer of Arcadia, a healthcare data analytics company, explains that the Make America Healthy Again initiative’s focus on chronic disease support will benefit value-based care and preventative care.

Accountable Care Organizations Still Play a Vital Role in Value-Based Care

Moving away from accountable care organizations (ACOs) will not lead to value-based care, according to Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company.

The Future of Value-Based Care During the Trump Administration

Luke Hansen, M.D., M.H.S., and chief medical officer of Arcadia, a healthcare data analytics company, said that achieving value-based care will need to be a multipronged approach with commercial purchasers and state Medicaid programs playing a prominent role.

Arcadia: Who They Are and Who They Serve

An overview of Arcadia, a healthcare data analytics company, according to chief medical officer, Luke Hansen, M.D., M.H.S.

Promising Early Results of Investigational Duchenne Muscular Dystrophy Therapy

Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of this year.

Official Media Partners

PBMI logo

Join the Community

an mjh life sciences brand

© 2022 MJH Life Sciences® and PBMI. All rights reserved.